drugset / Trial / NCT03595995
A Phase 2 Trial to Evaluate the Safety and Efficacy of UB-621
RandomizedParallel-groupDouble-blindTreatment
Summary
To evaluate the efficacy of two dose levels of UB-621 administration in reducing the HSV-2 genital shedding rate in patients with recurrent genital HSV-2 infection.
Timeline
- Start
- 2023-06-01
- Primary completion
- 2024-06-30
- Completion
- 2024-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | UB-621 | Monoclonal antibody | 2.5 mg/kg | Subcutaneous |
| Subject | UB-621 | Monoclonal antibody | 5 mg/kg | Subcutaneous |